Bio News
Shandong University team identifies the “SNRPF-DDX24-E2F4” feedback loop Targeted suppression with an ASO demonstrates efficacy in vivo and in patient-derived models

An ASO targeting SNRPF, a key oncogenic factor in ovarian cancer, was found to inhibit tumor growth. The ASO disrupts the “SNRPF-DDX24-E2F4” feedback loop, sequentially reducing expression of the DDX24 and E2F4 genes. Its efficacy was also demonstrated in in vivo and patient-derived xenograft models, positioning the loop as a potential new therapeutic target.

Biobook Team
biobookmedia@biobook.co.krCG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug
Biogen Signs $411 Million Deal With Trimtech for Neurodegenerative Diseases
AstraZeneca’s new myasthenia gravis drug cligepa approved in the U.S. and EU
Helus meets primary endpoint in phase 3 trial of depression drug candidate, with 7.6-point improvement over placebo